Outlook Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Fiscal first quarter ended December 31, 2020; comparative results are for the three months ended December 31, 2019. Outlook Therapeutics is a late clinical-stage biopharmaceutical company developing ONS-5010 (LYTENAVA), an ophthalmic bevacizumab formulation for retinal diseases, including wet age-related macular degeneration (wet AMD). The company had no approved products and no product-sales revenue.
Financial and operating metrics
| Metric | Quarter ended Dec. 31, 2020 | Quarter ended Dec. 31, 2019 / comparison |
|---|---|---|
| Revenue | No product-sales revenue; the filing does not provide a clear quarterly revenue figure. | — |
| Research and development expense | $11.9 million | $5.8 million; up $6.1 million |
| General and administrative expense | $2.2 million | $2.3 million; down $0.1 million |
| Operating loss | $14.2 million | $8.2 million |
| Net loss | $14.5 million | $16.6 million |
| Net loss per share, basic and diluted | $0.12 | $0.62 |
| Net cash used in operating activities | $13.3 million | $6.7 million |
| Cash at quarter-end | $5.6 million | $12.5 million at Sept. 30, 2020 |
| Current assets / current liabilities | $11.0 million / $12.1 million | At Dec. 31, 2020 |
| Total debt, net of unamortized loan costs | $11.1 million | $1.0 million at Sept. 30, 2020 |
| Stockholders’ equity (deficit) | $(10.5) million | $2.8 million at Sept. 30, 2020 |
Margins are not meaningful to the reported results because the company had no product sales. The filing identifies no separate quarterly revenue figure in the supplied text. The company reported a $14.5 million accumulated quarterly loss and a substantial accumulated deficit.
Material changes versus the prior comparable period
- Research and development expense more than doubled, primarily from ONS-5010 clinical development, NORSE THREE enrollment, and manufacturing scale-up and process-characterization work for the planned BLA.
- Operating cash use increased to $13.3 million from $6.7 million, while cash declined by $7.0 million during the quarter.
- Net loss was lower than the prior-year quarter despite the higher operating loss. The 2019 period included an $8.1 million debt-extinguishment loss and other preferred-stock and warrant-related items; weighted-average shares also increased substantially, affecting per-share comparability.
- In November 2020, the company received $10.0 million in cash proceeds from a new unsecured note. Debt increased materially; the note bears 7.5% annual interest and matures January 1, 2022.
- General and administrative expense was roughly flat, as higher stock-based compensation and professional fees were offset by lower facilities costs, including a $0.7 million gain on settling a lease-termination obligation.
Outlook, risks, contingencies, and unusual items
- Clinical and regulatory outlook: NORSE TWO, a pivotal Phase 3 wet AMD trial, completed enrollment in July 2020; topline results were expected in the third calendar quarter of 2021. NORSE THREE enrollment was completed in October 2020. Management planned to submit the ONS-5010 wet AMD BLA in December 2021 and intended to initiate additional BRVO and DME registration trials after the BLA submission.
- Liquidity and going concern: The filing states that recurring losses, negative operating cash flows, and debt raised substantial doubt about the company’s ability to continue as a going concern. Subsequent to quarter-end, a February 2021 public offering and concurrent private placements generated approximately $40.0 million net proceeds, and warrant exercises generated approximately $3.6 million gross proceeds. Management said these funds, together with December-quarter cash, were expected to fund operations through the planned BLA filing; it also said substantial additional financing would be required for future operations and commercialization.
- Financing and dilution: The February transactions included issuance of common shares at $1.00 per share and warrants to the underwriter. Common shares outstanding were 127.2 million at December 31, 2020 and 173.4 million on February 12, 2021. Future equity or debt financing, partnerships, or licensing arrangements may be needed; no assurance of successful financing was given.
- Debt terms: The unsecured note has a 14-month term, a 7.5% rate, and a 5% prepayment premium. Its default provisions include a 14% default rate and a 5% increase in the outstanding balance upon default. The company also had a $0.9 million PPP loan maturing in May 2022.
- Litigation: Laboratorios Liomont sued over a prior development, license, and supply agreement and claims $3.0 million in damages. Outlook disputes the claims and intends to defend them; the filing does not quantify a probable loss.
- COVID-19: Management said the pandemic had not significantly affected the quarter’s financial results and reported clinical and manufacturing activities active, while cautioning that future trial timelines could be disrupted.
- Other unusual item: The company recognized a $0.7 million gain after settling a prior lease-termination obligation. It also had a $0.9 million investment in a planned China joint venture that had not yet been formed; an additional contribution of approximately $2.1 million was expected within four years after formation.
Important facts for investors to verify
- Whether NORSE TWO results support the planned BLA timeline and whether the BLA was filed as expected.
- Actual cash runway after the February 2021 financing, subsequent spending, and any additional capital requirements.
- The full terms, outstanding balance, and repayment/default risks of the Streeterville unsecured note and PPP loan.
- Share count and potential dilution from the February offerings, underwriter warrants, and other outstanding securities.
- Developments in the $3.0 million Liomont claim and any resulting financial exposure.
- Whether the China joint venture was formed and whether the planned additional capital contribution or license obligations changed.